COPD

Inhaler technique informs health care outcomes in COPD management and should be a primary focus in patient education priorities.

Treatment pathways, including escalation and de-escalation of therapy, for patients with COPD are explored by a panel of medical experts.

This year’s most-read articles on chronic obstructive pulmonary disease (COPD) includes researchon early interventions and possible health policy solutions.

Patient education is critical for self-monitoring of COPD disease progression.

An expert panel discusses appropriate transitions and adjustments to COPD treatment approaches.

New study findings call into question the necessity of spirometry as a criterion for participation in palliative care research among patients with chronic obstructive pulmonary disease (COPD).

Higher mortality rates linked with chronic obstructive pulmonary disease (COPD) are found in individuals employed in the mining and food service industries, according to a CDC analysis.

Key opinion leaders highlight the triple therapy approach from the most recent GOLD guidelines, including ICS, long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA).

Inhaled corticosteroids (ICSs) are a key incorporation to COPD treatment strategies.

The role of combination therapy is explored for the treatment of COPD.

Social determinants of health (SDoH) can create major barriers for access to care.

The findings suggest that treatment with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) led to improvements and had a similar safety profile to both FF/VI and UMEC/VI regardless of patient chronic mucus hypersecretion status at baseline.

Global health policy should consider the impact of breathlessness symptoms in adults when addressing increasing rates of obesity, according to a recent study.

Social and economic burdens affecting patients with COPD provide significant obstacles to optimizing care.

Jeffrey D. Dunn, PharmD, MBA, leads a panel discussion on disease and treatment landscapes for COPD.

A risk prediction model may offer insight in evaluating depression and anxiety in patients with chronic obstructive pulmonary disease (COPD).

Results from a study on bronchoscopic lung volume reduction and lung volume reduction surgery may aid medical professionals in selecting the best treatment for patients with emphysema.

Better understanding of risk factors in patients with chronic obstructive pulmonary disease (COPD) and adverse childhood experiences (ACEs) may lead to better management in care.

The researchers said their findings lend support to the idea that urban and transportation planning policies should take into account the needs of patients with chronic disease.

Integrated primary care services may offer better outcomes in patients living with severe chronic obstructive pulmonary disease (COPD) without increasing costs.

The study found that combined therapeutic strategies may help lower the risk.

Continuing the race adjustment factors maintains health care disparities, the authors noted.

Inhaled corticosteroid (ICS) therapy was not the most appropriate treatment for many patients with chronic obstructive pulmonary disease (COPD) in a review of patient records at 2 US primary care clinics.

Patients with diabetes and chronic obstructive pulmonary disease (COPD) have worse outcomes when hospitalized and appear to be more vulnerable to respiratory and nonrespiratory complications after a COPD exacerbation, which highlights the need for targeted interventions in this population.

The authors modeled costs associated with a pedometer-based, web-mediated physical activity intervention compared with a pedometer alone for chronic obstructive pulmonary disease (COPD) management. The intervention was cost-saving.

The results show the importance of diagnosing lung conditions through spirometry as well the necessity for more effective therapies for patients without COPD.

While there are a number of treatment options available for patients with chronic obstructive pulmonary disease, not all options are right for all patients.

While there are a number of treatment options available for patients with chronic obstructive pulmonary disease, not all options are right for all patients.

The researchers noted these improvements were seen without an increase in hyperlactatemia risk.

Beyond smoking, the environment patients live in as well as their occupational risk factors all play large roles in the development of chronic obstructive pulmonary disease (COPD).